Rationale for choosing antihypertensive therapy in a patient with NAFLD and arterial hypertension
https://doi.org/10.31146/1682-8658-ecg-229-9-86-95
Abstract
The concept of metabolic syndrome (MS) has existed since the 1980s and in its classical version includes obesity, lipid and carbohydrate metabolism disorders, and arterial hypertension (AH). Later (since 2009), non-alcoholic fatty liver disease (NAFLD) was considered as the fifth component of MS, which is currently proposed to be renamed steatotic liver disease by the International Working Group “Multi-Society and Multi-Stakeholder Consensus Revision of the NAFLD Nomenclature”. NAFLD and AH are pathogenetically interconnected through insulin resistance, systemic inflammatory response and oxidative stress, progressive endothelial dysfunction, impaired vasoconstriction and vasodilation mechanisms that develop against the background of liver fibrogenesis, which is described in detail in this article. Patients with hypertension and NAFLD often have unstable hypertension with episodes of hypotension, and insufficient effectiveness of antihypertensive therapy. NAFLD itself is associated not only with an increased risk of cardiovascular events, but also with other cardiac complications, regardless of traditional cardiovascular risk factors. At the same time, hypertension increases the risk of liver cirrhosis and, in addition, hypertension is independently associated with the development of severe liver diseases. In other words, the combination of NAFLD and hypertension in a patient worsens the course of both pathologies and the patient’s prognosis, especially with progressive fibrosis in the liver. Pathogenetically substantiated drugs of choice in the treatment of hypertension in a patient with NAFLD are drugs that affect the renin-angiotensin system, which will also be discussed in this article.
About the Authors
S. N. Mekhtiyev
Pavlov First Saint Petersburg State Medical University; Gastroenterology center “Expert”
Russian Federation
Russian Federation
O. A. Mekhtiyeva
Pavlov First Saint Petersburg State Medical University; Gastroenterology center “Expert”
Russian Federation
Russian Federation
O. M. Berko
North-Western district scientific and clinical center named after L.G. Sokolov Federal Medical and Biological Agency
Russian Federation
Russian Federation
References
1. Uchil D, Pipalia D, Chawla M, Patel R, Maniar S, Narayani, Juneja A. Non-alcoholic fatty liver disease (NAFLD)-the hepatic component of metabolic syndrome. J Assoc Physicians India. 2009 Mar;57:201-4.
2. Lazebnik L.B. Steatotic liver disease - an international interpretation of the concept an “umbrella” for all diseases of the hepatic parenchyma. Experimental and Clinical Gastroenterology. 2023;(8):24-26. (In Russ.) doi: 10.31146/1682-8658-ecg-216-8-24-26.@@ Лазебник Л.Б. Steatotic liver disease - стеатозная болезнь печени - международная трактовка понятия «зонтика» для всех заболеваний печеночной паренхимы. Экспериментальная и клиническая гастроэнтерология. 2023;216(8): 24-26. doi: 10.31146/1682-8658-ecg-216-8-24-26.
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431.
4. Riazi K., Azhari H., Charette J.H. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0.
5. Younossi Z.M., Golabi P., Paik J.M., Henry A., Van Dongen C., Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004.
6. Ivashkin V.T., Drapkina O.M., Maev I.V. et al. [Prevalence of non-alcoholic fatty liver disease in outpatients in the Russian Federation: results of the DIREG 2 study].Russian Journal of Gastroenterology, Hepatology, Proctology. 2015;25(6):31-41 (in Russ.)@@ Ивашкин В.Т., Драпкина О.М., Маев И.В., и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(6):31-41.
7. Erina A.M., Rotar O.P., Solntsev V.N., Shalnova S.A., Deev A.D., Baranova E.I., Konradi O.A., Boytsov S.A., Shlyakhto E.V. Epidemiology of Arterial Hypertension in Russian Federation - Importance of Choice of Criteria of Diagnosis. Kardiologiia. 2019;59(6):5-11. (In Russ.) doi: 10.18087/cardio.2019.6.2595.@@ Ерина А.М., Ротарь О.П., Солнцев В.Н., Шальнова С.А., Деев А.Д., Баранова Е.И., Конради А.О., Бойцов С.А., Шляхто Е.В. Эпидемиология артериальной гипертензии в Российской Федерации - важность выбора критериев диагностики. Кардиология. 2019;59(6):5-11. doi: 10.18087/cardio.2019.6.2595.
8. Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, Asch SM, El-Serag HB. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020 Mar;71(3):808-819. doi: 10.1002/hep.31014.
9. Ciardullo S, Grassi G, Mancia G, Perseghin G. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022 Apr 1;34(4):365-371. doi: 10.1097/MEG.0000000000002299.
10. Ng C.H., Wong Z.Y., Chew N.W.S. et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med. 2022 Aug 8;9:942753. doi: 10.3389/fcvm.2022.942753.
11. Aneni E.C., Oni E.T., Martin S.S. et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015 Jun;33(6):1207-14. doi: 10.1097/HJH.0000000000000532.
12. Ciardullo S., Monti T., Sala I., Grassi G., Mancia G., Perseghin G. Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertension. 2020 Aug;76(2):562-568. doi: 10.1161/HYPERTENSIONAHA.120.15220.
13. Pirola C.J., Sookoian S. Non-alcoholic fatty liver disease mediates the effect of obesity on arterial hypertension. Liver Int. 2023 Oct;43(10):2167-2176. doi: 10.1111/liv.15643.
14. Ma C., Yan K., Wang Z., Zhang Q., Gao L., Xu T., Sai J., Cheng F., Du Y. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. Bioengineered. 2021 Dec;12(1):2187-2202. doi: 10.1080/21655979.2021.1933302.
15. Nakagami H. Mechanisms underlying the bidirectional association between nonalcoholic fatty liver disease and hypertension. Hypertens Res. 2023 Feb;46(2):539-541. doi: 10.1038/s41440-022-01117-6.
16. Oikonomou D., Georgiopoulos G., Katsi V., Kourek C., Tsioufis C., Alexopoulou A., Koutli E., Tousoulis D. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? Eur J Gastroenterol Hepatol. 2018 Sep;30(9):979-985. doi: 10.1097/MEG. 0000000000001191.
17. Saad M.F., Rewers M., Selby J. et al. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension. 2004 Jun;43(6):1324-31. doi: 10.1161/01.HYP.0000128019.19363.f9.
18. Zhao Y.C., Zhao G.J., Chen Z., She Z.G., Cai J., Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension. 2020 Feb;75(2):275-284. doi: 10.1161/HYPERTENSIONAHA.119.13419.
19. Watt M.J., Miotto P.M., De Nardo W., Montgomery M.K. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019; 40:1367-1393. doi: 10.1210/er.2019-00034.
20. Yoo H.J., Choi K.M. Hepatokines as a Link between Obesity and Cardiovascular Diseases. Diabetes Metab J. 2015 Feb;39(1):10-5. doi: 10.4093/dmj.2015.39.1.10.
21. Meex R.C.R., Watt M.J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017; 13:509-520. doi: 10.1038/nrendo.2017.56.
22. Cai J., Xu M., Zhang X., Li H. Innate immune signaling in nonalcoholic fatty liver disease and cardiovascular diseases. Annu Rev Pathol. 2019; 14:153-184. doi: 10.1146/annurev-pathmechdis-012418-013003.
23. Cai J., Zhang X.J., Li H. Role of innate immune signaling in non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2018; 29:712-722. doi: 10.1016/j.tem.2018.08.003.
24. Wang W., Zhang Y., Yang L., Li H. The innate immune signaling in cancer and cardiometabolic diseases: friends or foes? Cancer Lett. 2017; 387:46-60. doi: 10.1016/j.canlet.2016.06.004.
25. Ferrara D., Montecucco F., Dallegri F., Carbone F. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J Cell Physiol. 2019; 234:21630-21641. doi: 10.1002/jcp.28821.
26. Artunc F., Schleicher E., Weigert C., Fritsche A., Stefan N., Häring H.U. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016; 12:721-737. doi: 10.1038/nrneph.2016.145.
27. Lonardo A., Nascimbeni F., Mantovani A., Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018; 68:335-352. doi: 10.1016/j.jhep.2017.09.021.
28. Haukeland J.W., Damås J.K., Konopski Z. et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006; 44:1167-1174. doi: 10.1016/j.jhep.2006.02.011.
29. Bai L., Li H. Innate immune regulatory networks in hepatic lipid metabolism. J Mol Med (Berl). 2019; 97:593-604. doi: 10.1007/s00109-019-01765-1.
30. Carnagarin R., Matthews V., Zaldivia M.T.K., Peter K., Schlaich M.P. The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. Br J Pharmacol. 2019; 176:1839-1852. doi: 10.1111/bph.14481.
31. Houghton D., Zalewski P., Hallsworth K. et al. The degree of hepatic steatosis associates with impaired cardiac and autonomic function. J Hepatol. 2019; 70:1203-1213. doi: 10.1016/j.jhep.2019.01.035.
32. Satou R., Penrose H., Navar L.G. Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr Hypertens Rep. 2018; 20:100. doi: 10.1007/s11906-018-0900-0.
33. Sinn D.H., Kang D., Jang H.R. et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study. J Hepatol. 2017; 67:1274-1280. doi: 10.1016/j.jhep.2017.08.024.
34. Adolph T.E., Grander C., Grabherr F., Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions.Int J Mol Sci. 2017; 18: e1649. doi: 10.3390/ijms18081649.
35. Rojas E., Rodríguez-Molina D., Bolli P., Israili Z.H., Faría J., Fidilio E., Bermúdez V., Velasco M. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep. 2014; 16:463. doi: 10.1007/s11906-014-0463-7.
36. Faulkner J.L., Belin de Chantemèle E.J. Sex differences in mechanisms of hypertension associated with obesity. Hypertension. 2018; 71:15-21. doi: 10.1161/HYPERTENSIONAHA.117.09980.
37. Swiderska M., Maciejczyk M., Zalewska A., Pogorzelska J., Flisiak R., Chabowski A. Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients. Free Radic Res. 2019:1-10. doi: 10.1080/10715762.2019.1635691.
38. Francque S.M., van der Graaff D., Kwanten W.J. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016; 65:425-443. doi: 10.1016/j.jhep.2016.04.005.
39. Polyzos S.A., Kountouras J., Patsiaoura K. et al. Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Ann Hepatol. 2012; 11:68-76.
40. Wang Y., Chen S., Yao T., Li D., Wang Y., Li Y., Wu S., Cai J. Homocysteine as a risk factor for hypertension: a 2-year follow-up study. PLoS One. 2014; 9: e108223. doi: 10.1371/journal.pone.0108223.
41. Serg M., Kampus P., Kals J., Zagura M., Muda P., Tuomainen T.P., Zilmer K., Salum E., Zilmer M., Eha J. Association between asymmetric dimethylarginine and indices of vascular function in patients with essential hypertension. Blood Press. 2011; 20:111-116. doi: 10.3109/08037051.2010.533821.
42. Richir M.C., Bouwman R.H., Teerlink T., Siroen M.P., de Vries T.P., van Leeuwen P.A. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. JPEN J Parenter Enteral Nutr. 2008; 32:613-621. doi: 10.1177/0148607108321702.
43. Dogru T., Genc H., Tapan S. et al. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Diabetes Res Clin Pract. 2012; 96:47-52. doi: 10.1016/j.diabres.2011.11.022.
44. Persico M., Masarone M., Damato A., Ambrosio M., Federico A., Rosato V., Bucci T., Carrizzo A., Vecchione C. Non alcoholic fatty liver disease and eNOS dysfunction in humans. BMC Gastroenterol. 2017; 17:35. doi: 10.1186/s12876-017-0592-y.
45. Li N., Zhang G.W., Zhang J.R., Jin D., Li Y., Liu T., Wang R.T. Non-alcoholic fatty liver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis. 2015; 25:218-223. doi: 10.1016/j.numecd.2014.10.002.
46. Sherlock Sh., Dooley J. Diseases of the liver and biliary tract. GEOTAR Medicine. 1999. 864 p. (in Russ.)@@ Шерлок Ш., Дули Дж. Заболевания печени и жёлчных путей. ГЭОТАР Медицина. - 1999 г. - 864 стр.
47. Tirikova O.V., Kozlova N.M., Eliseev S.M., Akimova V.I., Gumerov R.R., Karelina N.V., Ventsak E.V. Endothelial dysfunction in patients with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2022;(7):45-53. (In Russ.) doi: 10.31146/1682-8658-ecg-203-7-45-53.@@ Тирикова О.В., Козлова Н.М., Елисеев С.М., Акимова В.И., Гумеров Р.Р., Карелина Н.В., Венцак Е.В. Эндотелиальная дисфункция у пациентов с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2022;(7):45-53. doi: 10.31146/1682-8658-ecg-203-7-45-53.
48. Aird W.C. Endothelium as an organ system. Crit Care Med. 2004;32(5 Suppl):271-279.
49. Heil S.G., De Vriese A.S., Kluijtmans L.A., Mortier S., Den Heijer M., Blom H.J. The role of hyperhomocysteinemia in nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation. Cell Mol Biol (Noisy-le-grand). 2004 Dec;50(8):911-6.
50. Statsenko M.E., Streltsova A.M. The role of non-alcoholic fatty liver disease in the development of vascular rigidity and cardiovascular risk in patients with arterial hypertension. Experimental and Clinical Gastroenterology. 2021;(10):14-21. (In Russ.) doi: 10.31146/1682-8658-ecg-194-10-14-21.@@ Стаценко М.Е., Стрельцова А.М. Роль неалкогольной жировой болезни печени в развитии сосудистой ригидности и сердечно-сосудистого риска у больных с артериальной гипертензией. Экспериментальная и клиническая гастроэнтерология. 2021;(10):14-21. doi: 10.31146/1682-8658-ecg-194-10-14-21.
51. Hamaguchi M., Kojima T., Takeda N. et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007 Mar 14;13(10):1579-84. doi: 10.3748/wjg.v13.i10.1579.
52. Targher G., Corey K.E., Byrne C.D. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab. 2021 Mar;47(2):101215. doi: 10.1016/j.diabet.2020.101215.
53. Yi J., Wang L., Guo J., Ren X. Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease. Hepatol Commun. 2023 Jan 10;7(1): e0016. doi: 10.1097/HC9.0000000000000016.
54. Jarvis H., Craig D., Barker R., Spiers G., Stow D., Anstee Q.M., Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020 Apr 30;17(4): e1003100. doi: 10.1371/journal.pmed.1003100.
55. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.
56. Clinical guidelines «Non-alcoholic fatty liver disease in adults». 2022. Available at: https://cr.minzdrav.gov.ru/schema/748_1@@ Клинические рекомендации «Неалкогольная жировая болезнь печени у взрослых». 2022. Available: https://cr.minzdrav.gov.ru/schema/748_1
57. Clinical guidelines «Arterial hypertension in adults». 2020. Available at: https://cr.minzdrav.gov.ru/schema/62_2@@ Клинические рекомендации «Артериальная гипертензия у взрослых». 2020. Available: https://cr.minzdrav.gov.ru/schema/62_2
58. Zhang X., Wong G.L., Yip T.C. et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022 Aug;76(2):469-482. doi: 10.1002/hep.32294.
59. Sturzeneker M.C.S., de Noronha L., Olandoski M., Wendling L.U., Precoma D.B. Ramipril significantly attenuates the development of non-alcoholic steatohepatitis in hyperlipidaemic rabbits. Am J Cardiovasc Dis. 2019 Apr 15;9(2):8-17.
60. Meng C., Song Z., Zhang L., Geng Y., Sun J., Miao G., Liu P. Effects of losartan in patients with NAFLD: A meta-analysis of randomized controlled trial. Open Life Sci. 2023 Mar 21;18(1):20220583. doi: 10.1515/biol-2022-0583.
61. Gu L., Zhu Y., Lee M. et al. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc Natl Acad Sci U S A. 2023 May 9;120(19): e2300706120. doi: 10.1073/pnas.2300706120.
62. Hirata T., Tomita K., Kawai T. et al. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).Int J Endocrinol. 2013;2013:587140. doi: 10.1155/2013/ 587140.
63. Ostroumova O.D., Maksimov M.L., Bondarets O.V. Angiotensin-converting enzyme inhibitors in physician practice: similarities and differences. Medical Council. 2011; 5-6: 50-57. (in Russ.)@@ Остроумова О.Д., Максимов М.Л., Бондарец О.В. Ингибиторы ангиотензинпревращающего фермента в практике врача: сходства и различия. Медицинский совет. 2011; 5-6: 50-57.
64. Kareva E.N. Evolution of sartans or are all sartans the same? CLINICAL PHARMACOLOGY AND THERAPY. 2016; 25(3):11-21. (in Russ.)@@ Карева Е.Н. Эволюция сартанов или все ли сартаны одинаковы? КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ. 2016; 25(3):11-21.
65. Leonova M.V. Clinical pharmacology of AT II receptor antagonists: features of valsartan. Medical Council. 2014;17:66-71. (in Russ.)@@ Леонова М.В. Клиническая фармакология антагонистов рецепторов ат II: особенности валсартана. Медицинский совет. 2014;17:66-71.
66. Ratziu V., de Ledinghen V., Oberti F., Mathurin P., Wartelle-Bladou C., Renou C., Sogni P., Maynard M., Larrey D., Serfaty L., Bonnefont-Rousselot D., Bastard J.P., Rivière M., Spénard J.; FRESGUN. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011 May;54(5):1011-9. doi: 10.1016/j.jhep.2010.08.030.
67. Minushkin O.N., Frolova A.A., Shindina T.S., Kropova O.E., Mikhailova E.V. Ursodeoxycholic acid in gastroenterological practice. RMJ. 2018;1(1):18-22. (in Russ.)@@ Минушкин О.Н., Фролова А.А., Шиндина Т.С., Кропова О.Е., Михайлова Е.В. Урсодезоксихолевая кислота в гастроэнтерологической практике. РМЖ. 2018;1(1):18-22.
68. Zinovieva E.N., Mekhtiev S.N., Mekhtieva O.A. Modern aspects of pathogenetic treatment of non-alcoholic fatty liver disease. Effective pharmacotherapy. 2012;26(4):24-29. (in Russ.)@@ Зиновьева Е.Н., Мехтиев С.Н., Мехтиева О.А. Современные аспекты патогенетического лечения неалкогольной жировой болезни печени. Эффективная фармакотерапия. 2012;26(4):24-29.
69. Okovity S.V., Raikhelson K.L., Volnukhin A.V., Kudlai D.A. Hepatoprotective properties of glycyrrhizic acid. Experimental and Clinical Gastroenterology. 2020;(12):96-108. (In Russ.) doi: 10.31146/1682-8658-ecg-184-12-96-108.@@ Оковитый С.В., Райхельсон К.Л., Волнухин А.В., Кудлай Д.А. Гепатопротекторные свойства глицирризиновой кислоты. Экспериментальная и клиническая гастроэнтерология. 2020;184(12): 96-108. doi: 10.31146/1682-8658-ecg-184-12-96-108.
Review
For citations:
Mekhtiyev S.N., Mekhtiyeva O.A., Berko O.M. Rationale for choosing antihypertensive therapy in a patient with NAFLD and arterial hypertension. Experimental and Clinical Gastroenterology. 2024;(9):86-95. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-229-9-86-95
Views:
324
Email this article 